Express Mail Label No.: EV 312709807 US

Date of Deposit: November 5, 2003

Attorney Docket No. 22058-521

IN THE UNITED STATES FATE AND TRADEMARK OFFICE

APPLICANTS:

Keith, et al.

SERIAL

09/521,696

EXAMINER:

J. Seharaseyon

NUMBER:

FILING DATE:

March 9, 2000

ART UNIT:

1647

FOR:

USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED CYTOTOXICITY

Mail Stop IDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Express Mail N .: EV 312709807 US Date of Deposit: November 5, 2003

Please type a plus sign (+) in this box





PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	09/521,696	
	Filing Date	March 9, 2000	
INFORMATION DISCLOSURE	First Named Inventor	Keith	
(use as many sheets as necessary)	Group Art Unit	1647	
	Examiner Name	J. Seharaseyon	
	Attorney Docket Number	22058-521	

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	4,518,585	05/21/85	Mark, et al.	424	85	
	AB	5,215,895	06/01/93	Bennett, et al.	435	69.52	
	AC	5,270,181	12/14/93	McCoy, et al.	435	69.7	
	AD	5,292,646	03/08/94	McCoy, et al.	435	69.7	
	AE	5,496,830	03/05/96	Shapiro, et al.	514	283	
	AF	5,631,219	05/20/97	Rosenthal, et al.	514	6	
	AG	5,846,958	12/08/98	Capizzi, et al.	514	114	

			FOREIGN PATENT DOCUMENTS			
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	АН	WO 92/04455 -	GENETICS INSTITUTE, INC.	03/19/92	Yes	
	Al	WO 96/19574	GENETICS INSTITUTE, INC.	06/27/96	Yes	
	AJ	WO 99/37322	GENETICS INSTITUTE, INC.	07/29/99	Yes	
	AK	WO 00/74707	GENETICS INSTITUTE, INC.	12/14/00	Yes	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.